Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 235

The DOI matches its Crossref record.

Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models

Beltran, P. J., Mitchell, P., Moody, G., Chung, Y., Cajulis, E., Belmontes, B., Radinsky, R., Calzone, F.·2008·Journal of Clinical Oncology

Abstract

4617 Background: Binding of IGF-1 or IGF-2 to the type I insulin-like growth factor receptor (IGF-1R) activates intracellular signals important in the growth and survival of pancreatic tumors. AMG 479 is a fully human monoclonal antibody against IGF-1R currently in phase II clinical trials. AMG 479 exerts its anti-tumor activity by blocking ligand binding and inducing receptor downregulation in vivo. Methods: IGF-1R and Insulin Receptor (IR) levels were determined using FACS analysis or Meso Scale Detection (MSD). Level of IGF-1R and AKT phosphorylation were measured using MSD. Animal experiments were performed by injecting 5 million MiaPaCa or BxPC-3 cells subcutaneously into female athymic nude mice. Treatment began when xenografts (n=10/group) were approximately 200 mm3 and continued for the length of the experiment. AMG 479 and gemcitabine were dosed 2x/week intraperitoneally. Erlotinib was dosed orally every day. Repeated measures ANOVA was used to compare the efficacy of the treatment groups. Results: The ratios of IGF-1R to IR were 60:1 and 1.5:1 in the BxPC-3 and MiaPaCa cell lines, respectively. In vitro, AMG 479 blocked IGF-1 induced IGF-1R and AKT activation in both cell lines. In vivo, AMG 479 blocked IGF-1 induced IGF-1R activation in both cell lines but could only block AKT activation in the BxPC-3 cell line. Dose- dependent tumor growth inhibition by AMG 479 was observed in both human pancreatic carcinoma xenograft models. Maximal inhibition (70%) was achieved with a 300 μg/dose, 2x/week schedule. Analysis of tumor xenografts following AMG 479 treatment revealed significant down- regulation of IGF-1R expression (>60%). Since the survival signals driven by IGF-1R have been shown to convey resistance to traditional therapies, we tested the ability of AMG 479 to enhance the efficacy of gemcitabine or erlotinib in vivo. Both gemcitabine and erlotinib were significantly more effective in combination with AMG 479. Furthermore, the triple combination of optimal doses of AMG 479, erlotinib and gemcitabine resulted in tumor stasis and regression. Conclusions: These results demonstrate that IGF-1R blockade by AMG 479 inhibits AKT signaling and enhances the in vivo anti-tumor effects of approved therapies for the treatment of pancreatic carcinoma. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Amgen Amgen

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.26.15_suppl.4617

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 235

Metadata

Authors
Beltran, P. J., Mitchell, P., Moody, G., Chung, Y., Cajulis, E., Belmontes, B., Radinsky, R., & Calzone, F.
Venue
Journal of Clinical Oncology
Published
2008-05-20
Volume
26
Issue
15_suppl
Pages
4617-4617
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2270409815
Cited by
235
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models. https://app.cochat.ai/papers/10.1200/jco.2008.26.15_suppl.4617
The paper
Beltran, P. J., Mitchell, P., Moody, G., Chung, Y., Cajulis, E., Belmontes, B., Radinsky, R., & Calzone, F. (2008). Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.26.15_suppl.4617

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.